Nationwide Registry Data Reveal Trimester-Specific Link Between Maternal Iron Deficiency and Autism Risk in Children |

Why Is the Timing of Iron Deficiency in Pregnancy So Critical for Neurodevelopmental Outcomes?

The Swedish registry study led by Wiegersma and colleagues drew on decades of linked health data to examine whether the gestational timing of maternal anemia mattered for offspring neurodevelopmental outcomes. Their analysis revealed that anemia diagnosed before 30 weeks of gestation carried a markedly higher association with autism spectrum disorder than anemia first identified in the third trimester, suggesting that the developing brain is most vulnerable to iron deprivation during earlier developmental stages. This temporal pattern aligns with what neuroscientists understand about fetal brain maturation: the first and second trimesters are periods of rapid neuronal proliferation, cortical layering, and the initial establishment of white matter tracts that will later support complex cognitive and social functions.

Preclinical research supports the idea that iron plays a uniquely time-sensitive role in brain development. Studies in rodent models conducted by Georgieff and others have demonstrated that iron deficiency during the equivalent of human early gestation produces permanent alterations in hippocampal gene expression, even when iron stores are fully restored later. These changes affect genes involved in synaptic plasticity and signal transduction — pathways repeatedly implicated in autism. Notably, the registry data showed that anemia appearing only in the third trimester did not carry the same elevated ASD risk, reinforcing the concept of a critical developmental window during which adequate iron status is essential for typical neurodevelopment.

What Do Current Prenatal Screening Guidelines Miss About Iron Deficiency?

One of the most pressing clinical implications of the registry findings is the gap between current screening practices and early identification of iron deficiency. In many healthcare systems, prenatal iron status is assessed primarily through hemoglobin concentration at the booking visit. However, hemoglobin is a late marker — serum ferritin, which reflects stored iron, drops well before hemoglobin falls below diagnostic thresholds for anemia. A woman can have substantially depleted iron reserves with a normal hemoglobin reading, a state sometimes called iron deficiency without anemia. The registry study's finding that early-pregnancy anemia drives the ASD risk association suggests that by the time hemoglobin-based screening detects a problem, the critical developmental window may have already passed.

Several professional bodies have begun updating their positions in response to accumulating evidence. The British Society for Haematology recommends checking serum ferritin at booking for all pregnant women, with a threshold of 30 µg/L to define iron depletion. The American College of Obstetricians and Gynecologists (ACOG) recommends screening for iron deficiency anemia in pregnancy and treating confirmed cases, though implementation varies widely. In low- and middle-income countries, where the WHO estimates anemia prevalence among pregnant women exceeds 50% in some regions, universal daily supplementation of 30–60 mg elemental iron is already recommended regardless of individual testing. The registry data add a neurodevelopmental dimension to what has traditionally been framed as a maternal health and birth-weight issue, potentially strengthening the case for more aggressive early screening and treatment globally.

How Strong Is the Evidence Linking Prenatal Iron Status to Autism — and What Remains Unknown?

The Swedish cohort study is among the largest and most rigorously controlled investigations of prenatal nutrition and neurodevelopmental outcomes. Its strengths include prospective data collection through national registries (minimizing recall bias), adjustment for a wide range of confounders including maternal psychiatric history and socioeconomic status, and a follow-up period long enough to capture ASD diagnoses. A separate population-based study published in the American Journal of Epidemiology by Schmidt and colleagues also found associations between low maternal iron intake in early pregnancy and increased ASD risk, providing independent corroboration from a different population and study design. Together, these studies meet several Bradford Hill criteria for causation, including consistency, temporality, biological gradient, and plausibility.

However, important uncertainties persist. Because randomized trials withholding iron from deficient pregnant women would be unethical, researchers rely on observational evidence and natural experiments. Residual confounding — for instance, from dietary patterns, genetic factors affecting both iron metabolism and neurodevelopment, or co-occurring nutritional deficiencies — cannot be fully excluded. Additionally, it remains unclear whether iron supplementation initiated after deficiency is detected can fully reverse the associated neurodevelopmental risk, or whether prevention of deficiency from the outset is necessary. Ongoing prospective cohort studies incorporating detailed biomarker measurements and genetic data may help clarify these questions in the coming years.